1329166-62-2

Basic information

• Product Name: [3-bromo-4-(2-bromo-acetyl)-phenyl]-carbamic acid methyl ester
• Synonyms: [3-bromo-4-(2-bromo-acetyl)-phenyl]-carbamic acid methyl ester
• CAS NO: 1329166-62-2
• Molecular Weight: 350.994
• Mol File: 1329166-62-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: [3-bromo-4-(2-bromo-acetyl)-phenyl]-carbamic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [3-bromo-4-(2-bromo-acetyl)-phenyl]-carbamic acid methyl ester(1329166-62-2)
• EPA Substance Registry System: [3-bromo-4-(2-bromo-acetyl)-phenyl]-carbamic acid methyl ester(1329166-62-2)

Safety Data

• Hazardous Substances Data: 1329166-62-2(Hazardous Substances Data)

Upstream product

• 1329166-63-3 (4-acetyl-3-bromo-phenyl)-carbamic acid methyl ester 
• 1261497-12-4 1-(4-amino-2-bromophenyl)ethan-1-one 
• 1006-39-9 1-(2-bromo-4-fluorophenyl)ethanone 

Relevant articles and documents

Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker

A novel series of macrocyclic FXIa inhibitors was designed based on our lead acyclic phenyl imidazole chemotype. Our initial macrocycles, which were double-digit nanomolar FXIa inhibitors, were further optimized with assistance from utilization of structure-based drug design and ligand bound X-ray crystal structures. This effort resulted in the discovery of a macrocyclic amide linker which was found to form a key hydrogen bond with the carbonyl of Leu41 in the FXIa active site, resulting in potent FXIa inhibitors. The macrocyclic FXIa series, exemplified by compound 16, had a FXIa Ki = 0.16 nM with potent anticoagulant activity in an in vitro clotting assay (aPTT EC1.5x = 0.27 μM) and excellent selectivity against the relevant blood coagulation enzymes.

NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.